INEX - Durchbruch vor Gericht - Kurssprung vorprogrammiert! - 500 Beiträge pro Seite

[ollinbg]

INEX ist dieses Jahr schon sehr gut gelaufen - hatte Verträge z.B. mit Hana Bio. - und kam dann aber wegen einer Klage wieder weit zurück.
Hier hat Inex nun recht bekommen und kann die Ausgliederung in ein neues Unternehmen vornehmen.

Hier sind heute bestimmt 50% drinnen, da haben eine Menge auf den Beschluß gewartet!

Meine Meinung...




Hier die Meldung:

Inex Pharmaceuticals Receives Positive Court Outcome for Spin-out of Tekmira
11/24/2006

VANCOUVER, Nov. 24, 2006 (Canada NewsWire via COMTEX News Network) --
INEX Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that the British Columbia Supreme Court issued a favourable written ruling from the November 7 and 8, 2006 hearing with respect to the spin-out of Tekmira Pharmaceuticals Corporation ("Tekmira").

In its ruling, the Court approved the INEX Plan of Arrangement to transfer all of the Company's transferable assets and liabilities to Tekmira. This includes the 2001 agreements that created Protiva Biotherapeutics, Inc. ("Protiva"), and the ongoing litigation with Protiva. The Court rejected all motions raised by Protiva to block the spin-out of Tekmira. The Court's written ruling has been posted on INEX's website at www.inexpharm.com.

On September 20, 2006 shareholders of INEX voted 99.3% in favour of spinning out all of the Company's technology, products, cash and partnerships into Tekmira.

Timothy M. Ruane, President and Chief Executive Officer of INEX, said, "We are working to close the Tekmira spin-out as quickly as possible, and anticipate completion of this transaction by December 31, 2006. We remain confident in our legal and contractual positions versus Protiva, and we continue to make strong progress with our partners as we advance our products through development."

The dispute with Protiva relates to rights of certain drug delivery technology for the delivery of small interfering RNA ("siRNA"), a new class of oligonucleotide drugs. As part of the contractual agreements that created Protiva in 2001, INEX believes it has retained all rights to certain oligonucleotide delivery technology, including the delivery of siRNA. INEX also believes that any technology advancements made by Protiva and its collaborators or by INEX, for the delivery of oligonucleotides, are either owned by INEX or should be licensed to INEX on an exclusive, worldwide paid-up and royalty-free basis. The 2001 contractual agreements that created Protiva are posted on INEX's website at www.inexpharm.com. INEX is continuing to develop its siRNA delivery technology with its collaborator, Alnylam Pharmaceuticals, Inc., a leader in the development of therapeutics based on siRNA.

There is also an outstanding legal dispute between INEX and Protiva in the Superior Court of California. INEX has filed a motion to dismiss the law suit initiated by Protiva on the grounds that California is an inappropriate venue to settle a dispute between two British Columbia based companies and that the law suit filed in California is nearly identical to claims filed in British Columbia Supreme Court. The hearing in California, originally scheduled for December 15, 2006, has now been rescheduled to January 31, 2007.

The completion of the spin-out of Tekmira will allow INEX, having no pharmaceutical assets, to complete a financing with an investor group led by Sheldon Reid, a co-founder of Energy Capitol Resources Ltd. ("Investor Group"). The Investor Group will invest up to $5.6 million in INEX by way of convertible debentures. Upon conversion of the debenture following the completion of the reorganization, the Investor Group will hold 100% of non-voting shares in INEX and 80% of the total number of shares outstanding. Therefore, current INEX common shareholders will own 20% of the equity of INEX and 100% of the Tekmira shares. The Investor Group plans to raise additional capital and acquire a new business for INEX. The money received by INEX as part of the corporate reorganization will be paid to the previous holders of INEX's convertible debt as per the note purchase and settlement agreement announced June 20, 2006.

About INEX

INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about INEX and this news release can be found at www.inexpharm.com.

Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Inex's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Inex's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

INEX's common shares are traded on the Toronto Stock Exchange under the trading symbol "IEX".

SOURCE: Inex Pharmaceuticals Corporation

Investors: Ian Mortimer, Vice President, Finance and Chief Financial Officer, Phone: [phone]; Media: Karen Cook Boas, James Hoggan & Associates Inc., Phone: [phone], Email: [e-mail]

Copyright (C) 2006 CNW Group. All rights reserved.

[ollinbg]

Hier die letzten Zahlen:

FINANCIAL RESULTS

For the nine months ended September 30, 2006, INEX's net income was $20.9 million ($0.54 per common share, basic and fully diluted) as compared to a net loss of $5.3 million ($0.14 per common share, basic and fully diluted) for the comparable period in 2005. For the three months ended September 30, 2006, the Company's net income was $3.6 million ($0.09 per common share, basic and fully diluted) as compared to a net loss of $2.1 million ($0.05 per common share, basic and fully diluted) for the comparable period in 2005.


Und das ganze bei einem aktuellen Kurs von
0.245 Can$
bzw. einer Marktkap. von 10Mio Can$ ca.

Nur die Unsicherheit über die Gerichtsentscheidung hat den Kurs nicht nach oben schnellen lassen.

[ollinbg]

In Kanada fängts jetzt schon an und das bid steigt!

[ollinbg]

Wer in Kanada ordern will:
Euro / Kanadischer Dollar 1,48

Jetzt gibts vielleicht in Frankfurt noch welche zu günstigen Preisen, später aber vorsichtig sein! Ging mir beim letzten Kauf so, dass die das ask dann nachträglich nach oben gezogen und ordentlich verdient haben!

[sirlawrence]

Ist FFM nicht etwas markteng ?

[ollinbg]

Antwort auf Beitrag Nr.: 25.660.836 von sirlawrence am 24.11.06 15:04:34

Außerdem...

Im Moment liegen auf 0,17 glaub ich noch welche

[ollinbg]

bid 0.285

[ollinbg]

rt +25% auf 0.3 Can$

[ollinbg]

Noch wer mit eingestiegen?

Aktuell:
Open: 0.3
Previous Close: 0.31
Exchange of Last Sale: T
Time of Last Sale: 09:39:22
Tick: Unchanged
Bid: 0.305
Ask: 0.31
Size Bid/Ask: 16x13

Volume: 302,600

[ollinbg]

net income was $20.9 million ($0.54 per common share, basic and fully diluted)
0.54 !

aktueller Kurs:
0.32

da ist noch Luft nach oben


RT:
Last: 0.320
Change: +0.08
Percent Change: +32.65%
High: 0.32
Low: 0.295
Volume: 384,600
Price Data TableOpen: 0.3
Previous Close: 0.32
Exchange of Last Sale: T
Time of Last Sale: 09:49:38
Tick: Up
Bid: 0.315
Ask: 0.32
Size Bid/Ask: 10x24

[ollinbg]

Vielleicht wird langsam ja mal Luft geholt
Das wird ein schöner abend, wenn jetzt dann bald alle wach sind und sich die Meldung rumspricht.

aktuell
Last: 0.3350
Change: +0.09
Percent Change: +36.73%
High: 0.34
Low: 0.295
Volume: 445,600
Price Data Table
Open: 0.3
Previous Close: 0.335
Exchange of Last Sale: T
Time of Last Sale: 10:06:17
Tick: UpB
id: 0.33
Ask: 0.335
Size Bid/Ask: 6x40

[ollinbg]

So langsam kanns wieder weitergehen da drübern

rt:
Last: 0.310
Change: +0.07
Percent Change: +28.57%
High: 0.34Low: 0.295
Volume: 623,300
Price Data Table´
Open: 0.3
Previous Close: 0.31
Exchange of Last Sale: T
Time of Last Sale: 11:10:20
Tick: Up
Bid: 0.3Ask: 0.31
Size Bid/Ask: 47x20

[ollinbg]

So viel scheint sich doch nicht mehr zu tun, naja, der Tag nach Thanksgiving...


Hier mal die Meldung, was jetzt dann genau passiert:
Tekmira wird eine neue Gesellschaft mit all den Assets und Vertägen und OHNE Schulden!
Die Gesellschaft geht voll an die Inex-Aktionäre!



Inex Revises Plan of Arrangement to Spin Out
Tekmira Pharmaceuticals Corporation



For immediate release: July 11, 2006



Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will revise its Plan of Arrangement for spinning out Tekmira Pharmaceuticals Corporation in order to further increase the value of the spinout for INEX shareholders and to fulfill a commitment made under a debt purchase and settlement agreement with the previous holders of certain convertible promissory notes.


Timothy M. Ruane, President and Chief Executive Officer of INEX, said INEX common shareholders would own 100% of Tekmira under the new reorganization and Tekmira would own 100% of INEX’s technology, cash, products and partnership alliances.


“Our shareholders will benefit from owning 100% of Tekmira and will still have an equity position in INEX,” Ruane said. “Tekmira will be debt free and have a diversified product portfolio including the significant partnerships with Hana Biosciences, Inc. and Alnylam Pharmaceuticals, Inc. We believe this provides much greater value to our shareholders than our previous Tekmira spin-out plans.”


Under the previous plan of arrangement that was approved 98.3% by a shareholder vote January 26, 2006, INEX’s Targeted Immunotherapy technology platform and associated products and some cash were to be transferred to Tekmira and 69% of Tekmira shares were to be distributed to INEX common shareholders.


Highlights of the revised Plan of Arrangement:

All of the pharmaceutical assets from INEX’s two technology platforms, Targeted Chemotherapy and Targeted Immunotherapy, would be transferred to Tekmira;
All of INEX’s cash would be transferred to Tekmira;
INEX’s pharmaceutical partnerships with Hana Biosciences, Inc. and Alnylam Pharmaceuticals, Inc. would be transferred to Tekmira;
100% of Tekmira shares would be distributed to INEX common shareholders; and
INEX’s current management team and employees will join Tekmira and assume the same positions they occupy in INEX.

Completion of this revised plan would allow INEX, having no pharmaceutical assets, to complete a financing with an investor group led by Sheldon Reid, a co-founder of Energy Capitol Resources Ltd. (“Investor Group”). The Investor Group will invest up to $5.6 million in INEX by way of convertible debentures. Upon conversion of the debenture following the completion of the reorganization, the Investor Group will hold 100% of non-voting shares in INEX and 80% of the total number of shares outstanding. Therefore, current INEX common shareholders will own 20% of the equity of INEX after the spin-out of Tekmira. The Investor Group plans to raise additional capital and acquire a new business for INEX.


The money received by INEX as part of the corporate reorganization will be paid to the previous holders of INEX’s convertible debt as per the note purchase and settlement agreement announced June 20, 2006.


The conditions to closing the reorganization and the spin-out of Tekmira include the completion of due diligence by the Investor Group, the transfer of all assets and liabilities to Tekmira, and approvals from shareholders, the Toronto Stock Exchange and the Supreme Court of British Columbia. INEX anticipates mailing an information circular to shareholders in August 2006 and intends to complete a shareholder meeting in September 2006.


Product pipelines

INEX has two pipelines of novel products, Targeted Chemotherapy and Targeted Immunotherapy. The three products in the Targeted Chemotherapy pipeline, Marqibo, INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan), have been licensed to Hana. Hana is responsible for all future development and future expenses. Hana anticipates initiating pivotal trials for Marqibo in the second half of 2006 and initiating phase 1 clinical trials for INX-0125 in 2006 and for INX-0076 in 2007. INEX is supporting Hana to ensure the products can be advanced as quickly as possible and is being reimbursed for this support.


INEX is also using its liposomal delivery technology in collaboration with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to evaluate the systemic delivery of Alnylam’s RNAi therapeutics. This collaboration is evaluating multiple targets including apolipoprotein B (apoB), a protein involved in cholesterol metabolism. The INEX and Alnylam agreement will build on preliminary data published by Alnylam and its collaborators in Nature, the leading international journal of science, showing that the systemic delivery of an apoB RNAi therapeutic significantly reduced blood cholesterol levels.


Under the terms of the agreement, Alnylam has the option to execute a global exclusive license for specific RNAi therapeutic targets. The license agreement would include upfront license fees, future milestone payments and royalties as the products are commercialized. Alnylam also has the right to expand the option to negotiate license terms for additional targets.


Under the Targeted Immunotherapy platform, INEX’s lead internal product candidate is INX-0167. INX-0167 is based on the encapsulation of immunostimulatory oligonucleotides (short sequences of nucleic acids) in liposomes and combines the immunostimulatory properties of certain oligonucleotides into a single synthetic particle. Preclinical studies have demonstrated that INX-0167 enhances the number and potency of certain immune cells, including natural killer (NK) cells. The resultant increase in NK cell activity is important for the enhancement of the potency of monoclonal antibodies through a mechanism known as antibody-dependent cell mediated cytotoxicity (ADCC). INEX recently published promising preclinical data on INX-0167 at the Annual Meeting of the American Association of Immunologists held May 12-16, 2006 showing INX-0167 can generate a potent immune response in non-human primates. INEX anticipates initiating formal toxicology studies in the fourth quarter of 2006 to initiate a phase 1 clinical trial in the second half of 2007.


About INEX

INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about INEX and this news release can be found at www.inexpharm.com.


Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Inex’s stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Inex’s products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.


Contacts for Inex Pharmaceuticals Corporation


Investors
Ian Mortimer
Vice President, Finance and Chief Financial Officer
Phone: [phone]
Email: [e-mail]
Website: www.inexpharm.com


Media
Karen Cook Boas
James Hoggan & Associates Inc.
Phone: [phone]
Email: [e-mail]


INEX’s common shares are traded on the Toronto Stock Exchange under the trading symbol “IEX”.

[Scat]

PENG !

Nach den heutigen News gabs dann (endlich) in Can kein halten mehr.
-
0.620 +0.27 77.14% Volumen 5,747,810

nachdem es unter Schwankungen in den letten tagen schon immer weiter
ging ging es heute richtig ab.

Bin sehr gespannt was morgen in Can abgeht.

[Buddah]

wow!man beachte die Umsätze!